欧盟HMA药品数据库（European Union HMA Authorisation of Medicines DataBase）
MR编号SE/H/0415/001
药品名称Duodopa
活性成分
    • Carbidopa 5.0 mg/ml
    • Levodopa 20.0 mg/ml
剂型Intestinal gel
上市许可持有人AbbVie AB Sweden
参考成员国 - 产品名称Sweden (SE)
互认成员国 - 产品名称
    • Bulgaria (BG)
      Duodopa
    • Croatia (HR)
    • Romania (RO)
      DUODOPA 20 mg/ml + 5 mg/ml gel intestinal
    • Germany (DE)
    • Denmark (DK)
    • Slovenia (SI)
    • Belgium (BE)
    • Netherlands (NL)
    • Luxembourg (LU)
    • Iceland (IS)
    • United Kingdom (Northern Ireland) (XI)
    • Ireland (IE)
    • Liechtenstein (LI)
    • Austria (AT)
      Duodopa, 20 mg/ml + 5 mg/ml, Gel zur intestinalen Anwendung
    • France (FR)
    • Spain (ES)
      DUODOPA GEL INTESTINAL
    • Portugal (PT)
    • Italy (IT)
    • Greece (GR)
    • Norway (NO)
    • Finland (FI)
    • Poland (PL)
      Duodopa
    • Latvia (LV)
      Duodopa intestināls gels
    • Lithuania (LT)
      Duodopa 20/5mg/ml žarnyno gelis
    • Estonia (EE)
      Duodopa
    • Hungary (HU)
      Duodopa gél bélben történő alkalmazásra
    • Cyprus (CY)
      DUODOPA INTESTINAL GEL
    • Czechia (CZ)
    • Slovakia (SK)
许可日期2004/06/08
最近更新日期2025/09/22
药物ATC编码
    • N04BA02 levodopa and decarboxylase inhibitor
申请类型
  • TypeLevel1：Known Active Substance
  • TypeLevel2：Initial Application
  • TypeLevel3：Full Dossier Article 4.8 Di 65/65
  • TypeLevel4：Chemical Substance
  • TypeLevel5：Prescription Only
附件文件下载
市场状态Positive
©2006-2025 Drugfuture->European Union HMA Authorisation of Medicines DataBase